AngioDynamics (NASDAQ:ANGO) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded AngioDynamics from “hold” to “buy,” while the broader analyst consensus remains “Hold” with a $19.50 target price.
• AngioDynamics exceeded quarterly expectations, reporting adjusted EPS of -$0.07 versus the -$0.11 consensus and revenue of $86.61 million against estimates of $80.24 million.
• The stock opened at $15.75, near its 52-week high of $16.29; institutional investors own approximately 89.43% of shares, while a senior vice president recently sold 23,370 shares.

AngioDynamics (NASDAQ:ANGO - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

ANGO has been the subject of a number of other research reports. HC Wainwright upped their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Canaccord Genuity Group boosted their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of AngioDynamics in a report on Friday, July 17th. Finally, Zacks Research lowered AngioDynamics from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $19.50.

AngioDynamics Price Performance

ANGO stock opened at $15.75 on Friday. AngioDynamics has a 1 year low of $9.06 and a 1 year high of $16.29. The company has a market cap of $650.98 million, a P/E ratio of -18.10 and a beta of 0.33. The stock's fifty day moving average price is $13.96 and its 200-day moving average price is $12.05.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. As a group, analysts expect that AngioDynamics will post -0.25 earnings per share for the current year.

Insider Activity at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the business's stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new stake in AngioDynamics in the second quarter worth $64,000. Bank of America Corp DE purchased a new stake in AngioDynamics in the 2nd quarter worth about $4,490,000. Gallagher Fiduciary Advisors LLC bought a new stake in AngioDynamics in the second quarter worth about $589,000. Hsbc Holdings PLC bought a new stake in AngioDynamics in the second quarter worth about $356,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics during the second quarter valued at approximately $428,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source